InhibRx Biosciences, Inc
Clinical trials sponsored by InhibRx Biosciences, Inc, explained in plain language.
Clinical-stage biotech developing antibody therapeutics for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New antibody drug shows promise for rare bone cancer
Disease control OngoingThis phase 2 trial tests a drug called INBRX-109 in people with a rare bone cancer (conventional chondrosarcoma) that cannot be removed by surgery or has spread. The drug is a lab-made antibody designed to kill cancer cells. About 206 participants will receive either INBRX-109 or…
Phase 2 • Sponsor: Inhibrx Biosciences, Inc • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New drug duo aims to supercharge immunotherapy against head and neck cancer
Disease control OngoingThis study tests whether adding an experimental drug called INBRX-106 to the standard immunotherapy pembrolizumab (Keytruda) works better than pembrolizumab alone for people with advanced head and neck cancer that has spread or come back. About 410 participants whose tumors have …
Phase 2/3 • Sponsor: Inhibrx Biosciences, Inc • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC